Re:GlaxoSmithKline makes $300M investment in 23andMe, forms ...
by ethbro on Wednesday July 25, 2018 @07:19PM
(#17613806)
> Selling it to anyone who pays the price seems like a bad idea. Which is inevitably what will happen here the next time the company needs to "maximize shareholder value" [...]
23andMe is still held exclusively by private capital.
Nowhere in the reporting does it note GSK negotiated the right to resell 23andMe data. Furthermore, it specifically notes "[if an option is taken to extend the arrangement for a 5th year], GSK will become 23andMe’s exclusive drug target discovery collaborator."
23andMe is still held exclusively by private capital.
Nowhere in the reporting does it note GSK negotiated the right to resell 23andMe data. Furthermore, it specifically notes "[if an option is taken to extend the arrangement for a 5th year], GSK will become 23andMe’s exclusive drug target discovery collaborator."
Edit: See searine's thread below for a better discussion of why this is critically important to drug development https://news.ycombinator.com/item?id=17611775